|Dr. Felix Theeuwes D.Sc., Ph.D.||316.76k||N/A||79|
|Dr. James E. Brown D.V.M.||560.13k||N/A||60|
|Mr. Matthew J. Hogan M.B.A.||355.26k||N/A||57|
|Ms. Judy R. Joice||310.85k||N/A||60|
|Mr. Michael H. Arenberg J.D., M.B.A.||N/A||N/A||N/A|
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The companys advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery; and REMOXY ER, an investigational extended release pain relief drug. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd.; Impax Laboratories, Inc.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
DURECT Corporation’s ISS Governance QualityScore as of October 15, 2017 is 7. The pillar scores are Audit: 5; Board: 5; Shareholder Rights: 8; Compensation: 4.